Lyell Immunopharma, Inc. (LYEL) NASDAQ

17.75

+1.245(+7.55%)

Updated at October 20 01:29PM

Currency In USD

Valuation

Market Cap3.35B
Enterprise Value3.3B
P/E Ratio-0.74
PEG Ratio0
Price/Sales Ratio5,283.08
Price/Book Ratio0.82
Enterprise/Revenue4,412.96
Enterprise/EBITDA-1.32

Fiscal Year

Fiscal YearDecember 31, 2024
Most Recent QuarterJune 30, 2025

Profitability

Profit Margin-5,523.28
Operating Margin-5,935.98

Management Effectiveness

Return On Assets-0.86
Return On Equity-0.86

Income Statement

Revenue61,000
Revenue/Share0
Gross Profit61,000
EBITDA-200.64M
Net Income-342.99M
Diluted EPS-1.31

Balance Sheet

Total Cash276.79M
Total Cash/Share18.71
Total Debt46.6M
Total Debt/Equity0.16
Current Ratio7.65
Book Value Per Share20.21

Price History

52-Week Change-26.34
52-Week High30
52-Week Low7.65
Moving Average 50 Days13.41
Moving Average 200 Days11.34

Statistics

Average Volume53,990
Shares Outstanding19.21M
% Held by Institutions62.59

Dividend And Splits

Trailing Annual Dividend Rate0
Trailing Annual Dividend Yield0
Payout Ratio0
Last Split Factor1:20
Last Split DateJune 02, 2025